Evolution of a melanoma in situ to a sarcomatoid dedifferentiated melanoma. (16th March 2021)

• Record Type: Journal Article
• Authors: Chung, Jina; Shevchenko, Alina; Lee, Jason B.
• Is Part Of: Journal of cutaneous pathology. Volume 48:Number 7(2021)
• Page Start: 943
• Page End: 947
• Publication Date: 2021-03-16
• Subjects: atypical fibroxanthoma -- CD10 -- next‐generation sequence assay -- spindle cell melanoma -- sarcomatoid dedifferentiated melanoma; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616
• DOI: 10.1111/cup.14003
• Languages: English
• ISSNs: 0303-6987

Abstract

Abstract: Sarcomatoid dedifferentiated melanoma (SDDM) is a recently recognized subtype of melanoma that stains diffusely for CD10 and lacks the expression of the usual melanocytic markers including S100, SOX10, MITF, and Melan A. Advances in next‐generation DNA sequencing technology have facilitated the increased recognition of this rare, aggressive spindle cell melanoma. Herein, a case of relatively early lesion of SDDM arising in association with melanoma in situ is highlighted. A 72‐year‐old man with a history of previously treated melanoma in situ on the face five years prior presented with a new rapidly growing lesion within the scar of the treated site. A shave biopsy of the lesion revealed a centrally located 1.8‐mm deep, poorly differentiated spindle cell neoplasm in association with an adjacent recurrent melanoma in situ. The spindle cell component stained diffusely for CD10, but failed to stain for S100, SOX10, and Melan‐A while the melanoma in situ expressed all three melanocytic markers. Next‐generation DNA sequencing assay revealed mutations in NF1, CDKN2A, TP53, and TSC1 . A diagnosis of stage 2B SDDM arising in association with melanoma in situ was established based on the clinical context and genomic assay results.